Picture of Oncimmune Holdings logo

ONC Oncimmune Holdings Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-23.39%
3m-28.83%
6m+1.5%
1yr-54.44%
Volume Change (%)
10d/3m+45.35%
Price vs... (%)
52w High-58.78%
50d MA-18.28%
200d MA-11.29%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-55.95%
Return on Equity-650.9%
Operating Margin-340.63%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Aug 202431st Aug 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Oncimmune Holdings EPS forecast chart

Profile Summary

Oncimmune Holdings plc is a United Kingdom-based immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiaries include Oncimmune Americas LLC, Oncimmune Germany GmbH, and Oncimmune LLC, among others.

Directors

Last Annual
August 31st, 2023
Last Interim
February 28th, 2023
Incorporated
October 9th, 2015
Public Since
May 18th, 2016
No. of Employees
56
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
74,142,147

ONC Share Price Performance

Upcoming Events for ONC

Oncimmune Holdings PLC Annual Shareholders Meeting

Oncimmune Holdings PLC Annual Shareholders Meeting

Half Year 2024 Oncimmune Holdings PLC Earnings Release

Similar to ONC

Picture of Alliance Pharma logo

Alliance Pharma

gb flag iconLondon Stock Exchange

Picture of Animalcare logo

Animalcare

gb flag iconLondon Stock Exchange

Picture of AstraZeneca logo

AstraZeneca

gb flag iconLondon Stock Exchange

Picture of Beximco Pharmaceuticals logo

Beximco Pharmaceuticals

gb flag iconLondon Stock Exchange

Picture of BSF Enterprise logo

BSF Enterprise

gb flag iconLondon Stock Exchange

FAQ